Cullinan Therapeutics, Inc. (CGEM)
$0.00+$0.00 (+0.00%) TodayExtended Hours
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
https://www.cullinantherapeutics.comSEC filings for CGEM on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 38,000 | $750K |
| Grant or award | 8 | 148,849 | |
| Option exercise | 4 | 68,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
49 Form 4 filings on record, the earliest from Nov 7, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Mary Kay Fenton - Officer | Grant or award | Common Stock | 27 | $6.49 | $175 | |
| Nadim Ahmed - Officer | Open-market sale | Common Stock | 9,922 | $10.01 | $99K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 1,345 | $10.01 | $13K | |
| Jacquelyn L. Sumer - Officer | Open-market sale | Common Stock | 3,480 | $9.67 | $34K | |
| Jeffrey Alan Jones - Officer | Open-market sale | Common Stock | 4,632 | $9.67 | $45K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 2,898 | $9.67 | $28K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 2,148 | $12.38 | $27K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 995 | $11.90 | $12K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 4,000 | $12.30 | $49K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share | 165,667 | $8.40 | $1.39M | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 150,000 | $8.86 | $1.33M | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 32,217 | $7.84 | $253K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share ("Common Stock") | 15,032 | $7.59 | $114K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 51,500 | $7.94 | $409K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 626,043 | $6.70 | $4.19M | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 277,298 | $7.36 | $2.04M | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share ("Common Stock") | 556,300 | $6.46 | $3.59M | |
| Andrew R. Allen | Grant or award | Stock Option (Right to Buy) | 79,456 | $0.00 | - | |
| Mittie Doyle | Grant or award | Stock Option (Right to Buy) | 79,456 | $0.00 | - | |
| Nadim Ahmed - Officer | Open-market sale | Common Stock | 8,400 | $11.87 | $100K | |
| Jeffrey Alan Jones - Officer | Open-market sale | Common Stock | 4,632 | $11.41 | $53K | |
| Jacquelyn L. Sumer - Officer | Open-market sale | Common Stock | 3,482 | $11.41 | $40K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 4,693 | $11.41 | $54K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 3,489 | $12.52 | $44K | |
| Jennifer Michaelson - Officer | Open-market sale | Common Stock | 8,000 | $15.64 | $125K |
This is as far as the anonymous view goes. Create a free account for all 49 CGEM filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| JENNIFER MICHAELSON | Officer | 30,000 | $588K | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Cullinan Therapeutics, Inc. (CGEM) had 10 insider filings in the last 90 days, with the most recent on 2026-08-14. The full record for CGEM runs to 49 Form 4 filings, the earliest from 2024-11-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CGEM were filed in the last 90 days. 8 purchases are on record for this company.
2 insider sales of CGEM were filed in the last 90 days, totaling $750K.
This page tracks CGEM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CGEM to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
